Reversal of the anticoagulant effect of direct thrombin inhibitor dabigatran etexilate in acute ischemic stroke and intracranial hemorrhage using idarucizumab – A case study

---

Case Report

Author Details : Ashutosh N Shetty*, Nasli R Ichaporia, Amod Tilak, Sonesh Kalra

Volume : 5, Issue : 3, Year : 2019

Article Page : 176-180

https://doi.org/10.18231/j.ijn.2019.028

Suggest article by email

Get Permission

---

Abstract

The non-Vitamin K oral anticoagulants (NOACs) help prevent stroke in patients of atrial fibrillation.
However, management of patients on NOACs in emergency situations is a challenging prospect.
Idarucizumab is approved globally as well as in India as the specific reversal agent for dabigatran. We
report two cases with successful reversal using Idarucizumab in acute ischemic stroke and intracranial
hemorrhage.

Keywords: Atrial fibrillation, Bleeding, India, Stroke.

How to cite : Shetty A N, Ichaporia N R, Tilak A, Kalra S , Reversal of the anticoagulant effect of direct thrombin inhibitor dabigatran etexilate in acute ischemic stroke and intracranial hemorrhage using idarucizumab – A case study. IP Indian J Neurosci 2019;5(3):176-180

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.